期刊
NATURE REVIEWS DRUG DISCOVERY
卷 18, 期 5, 页码 358-378出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41573-019-0012-9
关键词
-
资金
- National Institutes of Health (NIH)
- CHDI Foundation
- Grace Science Foundation
Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field. Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with two AAV-based therapeutics gaining regulatory approval in Europe or the United States. Continued study of AAV biology and increased understanding of the associated therapeutic challenges and limitations will build the foundation for future clinical success.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据